About Genx Pharma Private Limited
Data last updated: 09 January 2026
Genx Pharma Private Limited is a private limited company based in Shaikpet, Telangana, India. It specialises in pharmaceutical retail and distribution, a part of the broader pharmaceuticals sector. Incorporated on 03 October 1996, the company has been in operation for over 30 years.
Registered with ROC Hyderabad under CIN U24239TG1996PTC025371.
Capital: an authorised share capital of ₹6 Cr and a paid-up capital of ₹5.47 Cr. Formerly known as Genx Pharma Private Limited and Genx Pharma Limited. It is led by directors Bandi Vamsikrishna and Srinivas Reddy Male.
Last AGM: 04 September 2025. Financial statements filed for year ended 31 March 2025. Office: Shaikpet, Telangana.
As per the financials filed for FY 2025, the company reported a revenue of ₹8,328, a growth of 0% compared to the previous year.
The company has a workforce of approximately 1 employees as per the latest available data.
The company is associated with 2 brands - Gennex Pharma, Genex Pharma. As per MCA filings, the company has satisfied charges of ₹60 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website genexpharma.co.in.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressSy. No. 83/1 Plot No. 16/A/1 & 16/A/2 19Th & 20Th Floor, Hetero Tower Commerzone Silpa Gram Craft Village, Shaikpet, Telangana, India – 500081
-
IndustryPharma, Pharmaceutical Retailers & Distributors
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Genx Pharma Private Limited
Genx Pharma Private Limited has undergone 2 name changes throughout its history. The company was previously known as Genx Pharma Private Limited, and Genx Pharma Limited. The current legal name is Genx Pharma Private Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Genx Pharma Private Limited | Current |
| Genx Pharma Limited | Previous |
CIN History of Genx Pharma Private Limited
Genx Pharma Private Limited has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24239TG1996PTC025371, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239TG1996PTC025371 | Current |
| U24239AP1996PTC025371 | Previous |
| U24239AP1996PLC025371 | Previous |
| U24239TG1996PLC025371 | Previous |
Associated Brands with Genx Pharma Private Limited
Genx Pharma Private Limited operates two associated brands: Gennex pharma and Genex Pharma. These brands represent Genx Pharma Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Specializes in APIs, pharmaceutical products, and regulatory services for the biopharma sector. | gennexpharma.com | |
| Genex Pharma focuses on manufacturing and exporting pharmaceutical products in various therapeutic areas. | genexpharma.co.in |
Competitors & Alternatives of Genx Pharma Private Limited
Brands and companies operating in the same space as Genx Pharma Private Limited include ProPharma Group, PharmaLex, Pharma-Bio Serv and 7 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
ProPharma Group
|
Provider of regulatory compliance solutions to pharmaceutical, biotechnology and medical device | Saint Paul, United States, United States | 2001 |
PharmaLex
|
CRO specializing in regulatory affairs and pharmacovigilance | Mannheim, Germany, Germany | 1998 |
Pharma-Bio Serv
|
Provider of regulatory compliance and validation support to life science industries | Dorado, Puerto Rico, United States | 1993 |
Validant
|
Regulatory, compliance, and quality consulting for GxP lifecycles is provided. | San Francisco, United States, United States | 2005 |
Technical Safety Services
|
Healthcare instrumentation, medical gas systems, and related devices are manufactured. | Berkeley, United States, United States | 1970 |
Mapi Group
|
Real world evidence and post-approval research services are provided. | Lyon, France, France | 1990 |
Clinical Outcomes Solutions
|
Regulatory support and consulting services are provided for clinical outcomes. | Tucson, United States, United States | 2013 |
Celegence
|
Regulatory consulting and solutions for pharmaceuticals and medical devices compliance. | Downers Grove, United States, United States | 2017 |
Trasis
|
Provides radiopharmaceutical equipment, synthesis solutions, and custom services for labs. | Ans, Belgium, Belgium | 2004 |
RLM Consulting
|
Provides regulatory support for bio-pharma from nonclinical to clinical development stages. | Namur, Belgium, Belgium | 2007 |
Business Activity of Genx Pharma Private Limited
Genx Pharma Private Limited is engaged in the principal business activity of trade, with detailed activities including wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | ********* |
Auditor Details of Genx Pharma Private Limited
Genx Pharma Private Limited is audited by M V Narayana Reddy & Co., for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| M V Narayana Reddy & Co., | blur-value | blur-value | blur-value |
Board of Directors of Genx Pharma Private Limited
Genx Pharma Private Limited is currently managed by 2 directors, with 8 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Bandi Vamsikrishna | Director | 26 Jul 2007 | 18 Years 11 Months | Current |
|
Srinivas Reddy Male
Also directs:
Idhant Estate Properties Llp, Daaruk Infratech Llp, Krishna Sahithi Reddy Properties Llp and 5 more
|
Director | 28 Oct 1999 | 26 Years 8 Months | Current |
Financials of Genx Pharma Private Limited FY 2025 filings available
Genx Pharma Private Limited reported revenue of ₹8,328 (up 0% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Genx Pharma Private Limited
As of FY 2023, Genx Pharma Private Limited's shareholding pattern shows 98.00% by promoters, 2.00% by public shareholders. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Genx Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 May 1997 | State Bank of India | ₹30 Lakh | Satisfied |
| 31 May 1997 | State Bank of India | ₹30 Lakh | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Genx Pharma Private Limited
Genx Pharma Private Limited has a workforce of 1 employees as of Apr 08, 2024.
Employee Count & EPFO Data of Genx Pharma Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Genx Pharma Private Limited
GSTIN & GST Filing Data of Genx Pharma Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Genx Pharma Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Genx Pharma Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Genx Pharma Private Limited
MSME Payment Delays by Genx Pharma Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Genx Pharma Private Limited
Subsidiaries & Group Companies of Genx Pharma Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Genx Pharma Private Limited with ownership details.
MCA Filings & Documents of Genx Pharma Private Limited
MCA Filings & Documents of Genx Pharma Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Genx Pharma Private Limited
Frequently Asked Questions about Genx Pharma Private Limited
Genx Pharma Private Limited is an active private limited company in the pharma sector based in Shaikpet, Telangana, India. It was incorporated on 03 October 1996 (30+ years old) and is registered under CIN U24239TG1996PTC025371. The company has 1 employees.
Genx Pharma Private Limited reported revenue of ₹8,328 for FY 2025 (up 0.00% YoY).
The current directors of Genx Pharma Private Limited are:
The primary industry of Genx Pharma Private Limited is pharma. The company specifically operates in pharmaceutical retailers and distributors. The company is currently active in this sector.
Genx Pharma Private Limited can be reached at the registered office: Sy. No. 831 Plot No. 16A1 & 16A2 19Th & 20Th Floor, Hetero Tower Commerzone Silpa Gram Craft Village, Shaikpet, Telangana, India – 500081, or through the website genexpharma.co.in.
The authorised capital is ₹6 Cr, and the paid-up capital is ₹5.47 Cr.